Skip to main content
. Author manuscript; available in PMC: 2014 Jul 14.
Published in final edited form as: Toxicol Pathol. 2012 Nov 28;41(5):744–760. doi: 10.1177/0192623312464308

Figure 10.

Figure 10

Hepatocellular carcinoma. Immunolabelling TGF-β1 (brown), hematoxylin counterstain. Most neoplastic hepatocytes display moderate cytoplasmic immunoreactivity for TGF-β1. The BPDECs in the adjacent compressed hepatic parenchyma are strongly positive for TGF-β1 as in control liver. Bar = 50 μm 40X.